CIK 0001357874
- Non-accelerated filer
- Smaller reporting company
PRECISION BIOSCIENCES INC
Sign in to watch- Ticker
- DTIL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- May 21
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 919-314-5512
- Business address
- 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM, NC, 27701
- Open-market buys, last 90 days
- $29,501
- in 3 filings
- Open-market sales, last 90 days
- $27,505
- in 1 filing, $28K under 10b5-1 plans
Net +$1,996. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 39 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-05-07 | KANE MATTHEW R. President and CEO | Option exercise · Employee Stock Option (Right to Buy) | −21,514 | 43,028 | ||
| 2021-04-21 | KANE MATTHEW R. President and CEO | Option exercise | +13,422 | $1.18 | $16K | 1,978,218 |
| 2021-04-21 | KANE MATTHEW R. President and CEO | Option exercise · Employee Stock Option (Right to Buy) | −13,422 | 0 | ||
| 2021-04-19 | JANTZ DEREK Chief Scientific Officer | Option exercise | +21,514 | $0.04 | $861 | 4,026,435 |
| 2021-04-19 | JANTZ DEREK Chief Scientific Officer | Sale | −9,676 | $8.69 | $84K | 4,016,759 |
| 2021-04-19 | JANTZ DEREK Chief Scientific Officer | Option exercise · Employee Stock Option (Right to Buy) | −21,514 | 64,542 | ||
| 2021-04-16 | JANTZ DEREK Chief Scientific Officer | Option exercise | +21,514 | $0.04 | $861 | 4,014,596 |
| 2021-04-16 | JANTZ DEREK Chief Scientific Officer | Sale | −9,675 | $8.84 | $86K | 4,004,921 |
| 2021-04-16 | JANTZ DEREK Chief Scientific Officer | Option exercise · Employee Stock Option (Right to Buy) | −21,514 | 86,056 | ||
| 2021-04-15 | JANTZ DEREK Chief Scientific Officer | Option exercise | +21,514 | $0.04 | $861 | 4,002,758 |
| 2021-04-15 | JANTZ DEREK Chief Scientific Officer | Sale | −9,676 | $8.76 | $85K | 3,993,082 |
| 2021-04-15 | JANTZ DEREK Chief Scientific Officer | Option exercise · Employee Stock Option (Right to Buy) | −21,514 | 107,570 | ||
| 2021-04-12 | KANE MATTHEW R. President and CEO | Option exercise | +21,514 | $0.04 | $861 | 1,974,537 |
| 2021-04-12 | KANE MATTHEW R. President and CEO | Sale | −9,741 | $8.67 | $84K | 1,964,796 |
| 2021-04-12 | KANE MATTHEW R. President and CEO | Option exercise · Employee Stock Option (Right to Buy) | −21,514 | 64,542 | ||
| 2021-04-12 | Frankel Stanley Director | Grant or award · Stock Option (Right to Buy) | +63,325 | 63,325 | ||
| 2021-04-09 | KANE MATTHEW R. President and CEO | Option exercise | +21,514 | $0.04 | $861 | 1,962,760 |
| 2021-04-09 | KANE MATTHEW R. President and CEO | Sale | −9,737 | $8.87 | $86K | 1,953,023 |
| 2021-04-09 | KANE MATTHEW R. President and CEO | Option exercise · Employee Stock Option (Right to Buy) | −21,514 | 86,056 | ||
| 2021-04-08 | KANE MATTHEW R. President and CEO | Option exercise | +21,514 | $0.04 | $861 | 1,950,982 |
Page 21 of 23 · 456 trades